Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

T-cell non-Hodgkin lymphoma.

Mujahid A Rizvi1, Andrew M Evens, Martin S Tallman

  • 1Division of Hematology/Oncology, Department of Medicine, Northwestern University Feinberg School of Medicine, 676 N St Clair St, Ste 850, Chicago, IL 60611, USA. m-rizvi@md.northwestern.edu

Blood
|October 8, 2005
PubMed
Summary

Peripheral T-cell lymphomas (PTCLs) are rare cancers. This review covers their features, diagnostics, and challenging treatments, highlighting the need for further research into targeted therapies.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Efficacy of post-transplant brentuximab vedotin maintenance by pre-transplant disease status in relapsed/refractory classic Hodgkin lymphoma.

Blood cancer journal·2026
Same author

Expert Opinion on the Diagnosis and Treatment of Hematologic Malignancies During Pregnancy.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Three-Year Follow-Up of Nivolumab-AVD Versus Brentuximab Vedotin-AVD in Adolescents With Advanced-Stage Classic Hodgkin Lymphoma on S1826.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Prognostic impact of extranodal disease on PET/CT in follicular lymphoma: results from a validation study with ECOG 2408.

Blood neoplasia·2025
Same author

An Individualized Prediction Model for Early-Stage Classic Hodgkin's Lymphoma.

NEJM evidence·2025
Same author

Nivolumab-AVD Versus Brentuximab Vedotin-AVD in Older Patients With Advanced-Stage Classic Hodgkin Lymphoma Enrolled on S1826.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2025

Area of Science:

  • Hematology
  • Oncology
  • Pathology

Background:

  • Peripheral T-cell lymphomas (PTCLs) encompass nine distinct clinicopathologic subtypes according to the WHO/EORTC classification.
  • These uncommon hematologic malignancies present unique clinical and pathological characteristics.
  • Recent advancements have improved understanding of PTCL pathogenesis, including specific chromosomal translocations and viral associations.

Purpose of the Study:

  • To review the clinical and pathological features of peripheral T-cell lymphomas.
  • To discuss the role of molecular studies in the diagnostic work-up of these lymphomas.
  • To highlight the challenges in diagnosing and treating PTCLs and suggest future research directions.

Main Methods:

  • Literature review focusing on clinical presentation, histopathology, and molecular alterations in PTCLs.

Related Experiment Videos

  • Discussion of current diagnostic criteria and the utility of molecular diagnostics.
  • Analysis of treatment strategies and outcomes, considering the rarity of these diseases.

    • Main Results:

    • PTCLs are a heterogeneous group of disorders requiring individualized approaches.
    • Molecular studies are increasingly important for accurate diagnosis and understanding pathogenesis.
    • Treatment remains challenging due to disease rarity and limited clinical trial data.

    Conclusions:

    • Peripheral T-cell lymphomas require specialized diagnostic and therapeutic strategies.
    • Further research into PTCL biology is essential for developing more effective, targeted therapies.
    • Improved understanding may lead to better patient outcomes in these rare lymphomas.